GT Biopharma (GTBP) Cash from Financing Activities (2010 - 2026)

GT Biopharma (GTBP) has reported Cash from Financing Activities for 16 consecutive years, with $4.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 643.51% year-over-year to $4.6 million; the TTM figure through Mar 2026 stood at $19.7 million (up 3104.38% YoY), while the FY2025 annual figure was $15.8 million, up 430.07% from the prior year.
• Cash from Financing Activities eased to $4.6 million in Q1 2026 per GTBP's latest filing, from $8.3 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $8.3 million in Q4 2025 and bottomed at -$1000.0 in Q4 2022.
• Historically, Cash from Financing Activities has averaged $3.8 million across 4 years, with a median of $4.6 million in 2026.
• On a YoY basis, Cash from Financing Activities climbed as much as 643.51% in 2026 and fell as far as 643.51% in 2026.
• GT Biopharma's Cash from Financing Activities stood at -$1000.0 in 2022, then soared by 626900.0% to $6.3 million in 2023, then jumped by 32.5% to $8.3 million in 2025, then plunged by 44.85% to $4.6 million in 2026.
• Business Quant data shows GTBP's Cash from Financing Activities at $4.6 million in Q1 2026, $8.3 million in Q4 2025, and $977000.0 in Q3 2025.